Bone Health in Primary Ovarian Insufficiency

ABSTRACT

The etiology of primary ovarian insufficiency (POI) may be genetic, autoimmune, or iatrogenic. Genetic conditions include 45,X, 46,XX and 46,XY POI, and POI associated with galactosemia and FMR premutations. Women with autoimmune polyglandular syndromes 1 and 2 may develop autoimmune POI, as may those who receive chemotherapy or radiotherapy. Hypogonadism in POI can result in reduced rates of bone mass accrual in adolescents and young women, and low bone density for age in older women. Measures to optimize bone density in women with POI include attention to lifestyle measures and hormone replacement. Resistance training and adequate calcium and vitamin D supplementation are essential, as is replacement of estrogen/progestin. Estrogen/progestin replacement may be problematic in women with estrogen-sensitive breast cancer who developed POI in the course of therapy for cancer. In these instances, bisphosphonates are an option. In particular, zoledronic acid has been used successfully in conjunction with chemotherapy, tamoxifen, and aromatase inhibitors.

KEYWORDS

Bone density - bone microarchitecture - bone turnover - estrogen - androgens - bisphosphonates

REFERENCES

• 1 Nelson L M. Clinical practice. Primary ovarian insufficiency.  N Engl J Med. 2009;  360 (6) 606-614
• 2 Ohlsson C, Bengtsson B A, Isaksson O G, Andreassen T T, Slootweg M C. Growth hormone and bone.  Endocr Rev. 1998;  19 (1) 55-79
• 3 Bachrach L K. Acquisition of optimal bone mass in childhood and adolescence.  Trends Endocrinol Metab. 2001;  12 (1) 22-28
• 4 Miller K K, Biller B M, Beauregard C et al.. Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study.  J Clin Endocrinol Metab. 2006;  91 (5) 1683-1690
• 5 Francucci C M, Romagni P, Camilletti A et al.. Effect of natural early menopause on bone mineral density.  Maturitas. 2008;  59 (4) 323-328
• 6 Gallagher J C. Effect of early menopause on bone mineral density and fractures.  Menopause. 2007;  14 (3 Pt 2) 567-571
• 7 Patel R, Blake G M, Fogelman I. Peripheral and central measurements of bone mineral density are equally strongly associated with clinical risk factors for osteoporosis.  Calcif Tissue Int. 2007;  80 (2) 89-96
• 8 Bachelot A, Rouxel A, Massin N POF-GIS Study Group et al. Phenotyping and genetic studies of 357 consecutive patients presenting with premature ovarian failure.  Eur J Endocrinol. 2009;  161 (1) 179-187
• 9 Uygur D, Sengül O, Bayar D, Erdinç S, Batioğlu S, Mollamahmutoglu L. Bone loss in young women with premature ovarian failure.  Arch Gynecol Obstet. 2005;  273 (1) 17-19
• 10 Popat V B, Calis K A, Vanderhoof V H et al.. Bone mineral density in estrogen-deficient young women.  J Clin Endocrinol Metab. 2009;  94 (7) 2277-2283
• 11 Leite-Silva P, Bedone A, Pinto-Neto A M, Costa J V, Costa-Paiva L. Factors associated with bone density in young women with karyotypically normal spontaneous premature ovarian failure.  Arch Gynecol Obstet. 2009;  280 (2) 177-181
• 12 Holroyd C R, Davies J H, Taylor P et al.. Reduced cortical bone density with normal trabecular bone density in girls with Turner syndrome.  Osteoporos Int. 2010;  21 (12) 2093-2099
• 13 Bakalov V K, Chen M L, Baron J et al.. Bone mineral density and fractures in Turner syndrome.  Am J Med. 2003;  115 (4) 259-264
• 14 Costa A M, Lemos-Marini S H, Baptista M T, Morcillo A M, Maciel-Guerra A T, Guerra Jr G. Bone mineralization in Turner syndrome: a transverse study of the determinant factors in 58 patients.  J Bone Miner Metab. 2002;  20 (5) 294-297
• 15 Gravholt C H, Lauridsen A L, Brixen K, Mosekilde L, Heickendorff L, Christiansen J S. Marked disproportionality in bone size and mineral, and distinct abnormalities in bone markers and calcitropic hormones in adult Turner syndrome: a cross-sectional study.  J Clin Endocrinol Metab. 2002;  87 (6) 2798-2808
• 16 Buzi F, Maccarinelli G, Guaragni B et al.. Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis.  Clin Endocrinol (Oxf). 2004;  60 (1) 87-91
• 17 Nissen N, Gravholt C H, Abrahamsen B et al.. Disproportional geometry of the proximal femur in patients with Turner syndrome: a cross-sectional study.  Clin Endocrinol (Oxf). 2007;  67 (6) 897-903
• 18 Bakalov V K, Bondy C A. Fracture risk and bone mineral density in Turner syndrome.  Rev Endocr Metab Disord. 2008;  9 (2) 145-151
• 19 Bakalov V K, Axelrod L, Baron J et al.. Selective reduction in cortical bone mineral density in turner syndrome independent of ovarian hormone deficiency.  J Clin Endocrinol Metab. 2003;  88 (12) 5717-5722
• 20 Gravholt C H, Vestergaard P, Hermann A P, Mosekilde L, Brixen K, Christiansen J S. Increased fracture rates in Turner's syndrome: a nationwide questionnaire survey.  Clin Endocrinol (Oxf). 2003;  59 (1) 89-96
• 21 Zuckerman-Levin N, Yaniv I, Schwartz T, Guttmann H, Hochberg Z. Normal DXA bone mineral density but frail cortical bone in Turner's syndrome.  Clin Endocrinol (Oxf). 2007;  67 (1) 60-64
• 22 Landin-Wilhelmsen K, Bryman I, Windh M, Wilhelmsen L. Osteoporosis and fractures in Turner syndrome—importance of growth promoting and oestrogen therapy.  Clin Endocrinol (Oxf). 1999;  51 (4) 497-502
• 23 Han T S, Cadge B, Conway G S. Hearing impairment and low bone mineral density increase the risk of bone fractures in women with Turner's syndrome.  Clin Endocrinol (Oxf). 2006;  65 (5) 643-647
• 24 Michala L, Goswami D, Creighton S M, Conway G S. Swyer syndrome: presentation and outcomes.  BJOG. 2008;  115 (6) 737-741
• 25 Benetti-Pinto C L, Bedone A, Magna L A, Marques-Neto J F. Factors associated with the reduction of bone density in patients with gonadal dysgenesis.  Fertil Steril. 2002;  77 (3) 571-575
• 26 Han T S, Goswami D, Trikudanathan S, Creighton S M, Conway G S. Comparison of bone mineral density and body proportions between women with complete androgen insensitivity syndrome and women with gonadal dysgenesis.  Eur J Endocrinol. 2008;  159 (2) 179-185
• 27 Allen E G, Sullivan A K, Marcus M et al.. Examination of reproductive aging milestones among women who carry the FMR1 premutation.  Hum Reprod. 2007;  22 (8) 2142-2152
• 28 Panis B, Forget P P, van Kroonenburgh M J et al.. Bone metabolism in galactosemia.  Bone. 2004;  35 (4) 982-987
• 29 Berry G T. Galactosemia and amenorrhea in the adolescent.  Ann N Y Acad Sci. 2008;  1135 112-117
• 30 Kaufman F R, Loro M L, Azen C, Wenz E, Gilsanz V. Effect of hypogonadism and deficient calcium intake on bone density in patients with galactosemia.  J Pediatr. 1993;  123 (3) 365-370
• 31 Rubio-Gozalbo M E, Hamming S, van Kroonenburgh M J, Bakker J A, Vermeer C, Forget P P. Bone mineral density in patients with classic galactosaemia.  Arch Dis Child. 2002;  87 (1) 57-60
• 32 Molina J R, Barton D L, Loprinzi C L. Chemotherapy-induced ovarian failure: manifestations and management.  Drug Saf. 2005;  28 (5) 401-416
• 33 Bines J, Oleske D M, Cobleigh M A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer.  J Clin Oncol. 1996;  14 (5) 1718-1729
• 34 Bruning P F, Pit M J, de Jong-Bakker M, van den Ende A, Hart A, van Enk A. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer.  Br J Cancer. 1990;  61 (2) 308-310
• 35 Hadji P, Ziller M, Maskow C, Albert U, Kalder M. The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer.  Eur J Cancer. 2009;  45 (18) 3205-3212
• 36 Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I. Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer.  Br J Cancer. 1997;  75 (2) 301-305
• 37 Tham Y L, Sexton K, Weiss H L, Elledge R M, Friedman L C, Kramer R M. The adherence to practice guidelines in the assessment of bone health in women with chemotherapy-induced menopause.  J Support Oncol. 2006;  4 (6) 295-298 304
• 38 McCune W J, Saluja M, Bhat S, Lange L A, Holzman L, Johnson K. Correlation of membranous glomerular ultrastructural changes with disease severity and outcome in lupus patients initiating cyclophosphamide therapy.  Lupus. 2005;  14 (6) 426-433
• 39 Davies J H, Evans B A, Jenney M E, Gregory J W. In vitro effects of combination chemotherapy on osteoblasts: implications for osteopenia in childhood malignancy.  Bone. 2002;  31 (2) 319-326
• 40 Kanis J A, McCloskey E V, Powles T, Paterson A H, Ashley S, Spector T. A high incidence of vertebral fracture in women with breast cancer.  Br J Cancer. 1999;  79 (7-8) 1179-1181
• 41 Headley J A, Theriault R L, LeBlanc A D, Vassilopoulou-Sellin R, Hortobagyi G N. Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy.  Cancer Invest. 1998;  16 (1) 6-11
• 42 Powles T J, McCloskey E, Paterson A H et al.. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer.  J Natl Cancer Inst. 1998;  90 (9) 704-708
• 43 Pfeilschifter J, Diel I J. Osteoporosis due to cancer treatment: pathogenesis and management.  J Clin Oncol. 2000;  18 (7) 1570-1593
• 44 Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.  J Clin Oncol. 2006;  24 (4) 675-680
• 45 Imai A, Furui T. Chemotherapy-induced female infertility and protective action of gonadotropin-releasing hormone analogues.  J Obstet Gynaecol. 2007;  27 (1) 20-24
• 46 Blumenfeld Z, Dann E, Avivi I, Epelbaum R, Rowe J M. Fertility after treatment for Hodgkin's disease.  Ann Oncol. 2002;  13 (Suppl 1) 138-147
• 47 Pereyra Pacheco B, Méndez Ribas J M, Milone G et al.. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report.  Gynecol Oncol. 2001;  81 (3) 391-397
• 48 Mardesic T, Snajderova M, Sramkova L, Keslova P, Sedlacek P, Stary J. Protocol combining GnRH agonists and GnRH antagonists for rapid suppression and prevention of gonadal damage during cytotoxic therapy.  Eur J Gynaecol Oncol. 2004;  25 (1) 90-92
• 49 Recchia F, Sica G, De Filippis S, Saggio G, Rosselli M, Rea S. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study.  Anticancer Drugs. 2002;  13 (4) 417-424
• 50 Cumber P M, Whittaker J A. Ovarian failure after total body irradiation.  BMJ. 1990;  300 (6722) 464
• 51 Kondo H, Searby N D, Mojarrab R et al.. Total-body irradiation of postpubertal mice with (137)Cs acutely compromises the microarchitecture of cancellous bone and increases osteoclasts.  Radiat Res. 2009;  171 (3) 283-289
• 52 Nakagawa K, Kanda Y, Yamashita H et al.. Ovarian shielding allows ovarian recovery and normal birth in female hematopoietic SCT recipients undergoing TBI.  Bone Marrow Transplant. 2008;  42 (10) 697-699
• 53 Feng W, Cui Y, Zhan H et al.. Prevention of premature ovarian failure and osteoporosis induced by irradiation using allogeneic ovarian/bone marrow transplantation.  Transplantation. 2010;  89 (4) 395-401
• 54 Chao H T, Wang P H, Yuan C C, Lee W L. Successful pregnancy in a woman with acute myeloid leukemia treated with high-dose whole-body irradiation.  J Reprod Med. 1998;  43 (8) 703-706
• 55 Jacob A, Goodman A, Holmes J. Fertility after bone marrow transplantation following conditioning with cyclophosphamide and total body irradiation.  Bone Marrow Transplant. 1995;  15 (3) 483-484
• 56 Rahhal S N, Eugster E A. Unexpected recovery of ovarian function many years after bone marrow transplantation.  J Pediatr. 2008;  152 (2) 289-290
• 57 Samuelsson A, Fuchs T, Simonsson B, Björkholm M. Successful pregnancy in a 28-year-old patient autografted for acute lymphoblastic leukemia following myeloablative treatment including total body irradiation.  Bone Marrow Transplant. 1993;  12 (6) 659-660
• 58 Bakker B, Massa G G, Oostdijk W, Van Weel-Sipman M H, Vossen J M, Wit J M. Pubertal development and growth after total-body irradiation and bone marrow transplantation for haematological malignancies.  Eur J Pediatr. 2000;  159 (1-2) 31-37
• 59 Sarafoglou K, Boulad F, Gillio A, Sklar C. Gonadal function after bone marrow transplantation for acute leukemia during childhood.  J Pediatr. 1997;  130 (2) 210-216
• 60 Castelo-Branco C, Rovira M, Pons F et al.. The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation.  Maturitas. 1996;  23 (3) 307-312
• 61 Prince R L. Counterpoint: estrogen effects on calcitropic hormones and calcium homeostasis.  Endocr Rev. 1994;  15 (3) 301-309
• 62 Rebar R W. Premature ovarian failure.  Obstet Gynecol. 2009;  113 (6) 1355-1363
• 63 Lissett C A, Shalet S M. The impact of dose and route of estrogen administration on the somatotropic axis in normal women.  J Clin Endocrinol Metab. 2003;  88 (10) 4668-4672
• 64 Mah P M, Webster J, Jönsson P, Feldt-Rasmussen U, Koltowska-Häggström M, Ross R J. Estrogen replacement in women of fertile years with hypopituitarism.  J Clin Endocrinol Metab. 2005;  90 (11) 5964-5969
• 65 Canonico M, Oger E, Plu-Bureau G Estrogen and Thromboembolism Risk (ESTHER) Study Group et al.. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.  Circulation. 2007;  115 (7) 840-845
• 66 Scarabin P Y, Oger E, Plu-Bureau G. EStrogen and THromboEmbolism Risk Study Group . Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk.  Lancet. 2003;  362 (9382) 428-432
• 67 Popat V B, Vanderhoof V H, Calis K A, Troendle J F, Nelson L M. Normalization of serum luteinizing hormone levels in women with 46,XX spontaneous primary ovarian insufficiency.  Fertil Steril. 2008;  89 (2) 429-433
• 68 Bjarnason K, Cerin A, Lindgren R, Weber T. Scandinavian Long Cycle Study Group . Adverse endometrial effects during long cycle hormone replacement therapy.  Maturitas. 1999;  32 (3) 161-170
• 69 Gibbons W E, Moyer D L, Lobo R A, Roy S, Mishell Jr D R. Biochemical and histologic effects of sequential estrogen/progestin therapy on the endometrium of postmenopausal women.  Am J Obstet Gynecol. 1986;  154 (2) 456-461
• 70 DiVasta A D, Gordon C M. Hormone replacement therapy for the adolescent patient.  Ann N Y Acad Sci. 2008;  1135 204-211
• 71 Popat V B, Kalantaridou S, Reynolds J C et al.. Physiologic transdermal estradiol replacement therapy restores femoral neck bone density in women with spontaneous 46,XX primary ovarian insufficiency: 3 year randomized controlled clinical trial.  Fertil Steril. 2007;  88 S48
• 72 Crofton P M, Evans N, Bath L E et al.. Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover.  Clin Endocrinol (Oxf). 2010;  73 (6) 707-714
• 73 Saggese G, Baroncelli G I, Bertelloni S, Barsanti S. The effect of long-term growth hormone (GH) treatment on bone mineral density in children with GH deficiency. Role of GH in the attainment of peak bone mass.  J Clin Endocrinol Metab. 1996;  81 (8) 3077-3083
• 74 Ari M, Bakalov V K, Hill S, Bondy C A. The effects of growth hormone treatment on bone mineral density and body composition in girls with Turner syndrome.  J Clin Endocrinol Metab. 2006;  91 (11) 4302-4305
• 75 Aycan Z, Cetinkaya E, Darendeliler F et al.. The effect of growth hormone treatment on bone mineral density in prepubertal girls with Turner syndrome: a multicentre prospective clinical trial.  Clin Endocrinol (Oxf). 2008;  68 (5) 769-772
• 76 Suganuma N, Furuhashi M, Hirooka T et al.. Bone mineral density in adult patients with Turner's syndrome: analyses of the effectiveness of GH and ovarian steroid hormone replacement therapies.  Endocr J. 2003;  50 (3) 263-269
• 77 Sass T C, De Muinck Keizer-Schrama S M, Stijnen T et al.. A longitudinal study on bone mineral density until adulthood in girls with Turner's syndrome participating in a growth hormone injection frequency-response trial.  Clin Endocrinol (Oxf). 2000;  52 (5) 531-536
• 78 Hanton L, Axelrod L, Bakalov V, Bondy C A. The importance of estrogen replacement in young women with Turner syndrome.  J Womens Health (Larchmt). 2003;  12 (10) 971-977
• 79 Högler W, Briody J, Moore B, Garnett S, Lu P W, Cowell C T. Importance of estrogen on bone health in Turner syndrome: a cross-sectional and longitudinal study using dual-energy X-ray absorptiometry.  J Clin Endocrinol Metab. 2004;  89 (1) 193-199
• 80 Khastgir G, Studd J W, Fox S W, Jones J, Alaghband-Zadeh J, Chow J W. A longitudinal study of the effect of subcutaneous estrogen replacement on bone in young women with Turner's syndrome.  J Bone Miner Res. 2003;  18 (5) 925-932
• 81 Grey A B, Stapleton J P, Evans M C, Tatnell M A, Ames R W, Reid I R. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women.  Am J Med. 1995;  99 (6) 636-641
• 82 Love R R, Mazess R B, Barden H S et al.. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.  N Engl J Med. 1992;  326 (13) 852-856
• 83 Resch A, Biber E, Seifert M, Resch H. Evidence that tamoxifen preserves bone density in late postmenopausal women with breast cancer.  Acta Oncol. 1998;  37 (7-8) 661-664
• 84 Delmas P D, Ensrud K E, Adachi J D Mulitple Outcomes of Raloxifene Evaluation Investigators et al.. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.  J Clin Endocrinol Metab. 2002;  87 (8) 3609-3617
• 85 Ettinger B, Black D M, Mitlak B H Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial.  JAMA. 1999;  282 (7) 637-645
• 86 Ramaswamy B, Shapiro C L. Osteopenia and osteoporosis in women with breast cancer.  Semin Oncol. 2003;  30 (6) 763-775
• 87 Gnant M, Mlineritsch B, Luschin-Ebengreuth G Austrian Breast and Colorectal Cancer Study Group (ABCSG) et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.  Lancet Oncol. 2008;  9 (9) 840-849
• 88 Gnant M F, Mlineritsch B, Luschin-Ebengreuth G Austrian Breast and Colorectal Cancer Study Group et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.  J Clin Oncol. 2007;  25 (7) 820-828
• 89 Vehmanen L, Saarto T, Elomaa I, Mäkelä P, Välimäki M, Blomqvist C. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment.  Eur J Cancer. 2001;  37 (18) 2373-2378